Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer

Status Terminated

Clinical Trial Summary

The purpose of this study is to learn about the effect of the investigational agent tivozanib on the control of the tumor growth in hepatocellular (liver) cancer. The investigators also plan to collect information on the likelihood to develop side effects while on this treatment. Tivozanib is an oral medication (pill) taken once a day. This medication is designed to stop the tumor from developing new blood vessels.

Clinical Trial Description

Angiogenesis is the formation of new blood vessels. Angiogenesis is driven by cytokines including vascular endothelial growth factor. Tivozanib is an oral medication that inhibits vascular endothelial growth factor preventing tumor from developing new blood vessels.

The purpose of this study is to evaluate the effects of tivozanib on hepatocellular (liver) cancer. Participants in the study take tivozanib daily at a dose of 1 mg for 1month. if doing well the dose would be increased to 1.5 mg per day. Patients are monitored for response using CT or MRI scans every 2months. In addition, patients will have blood draws to evaluate the effects of tivozanib on blood vessels. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01807156
Study type	Interventional
Source	Emory University
Contact
Status	Terminated
Phase	Phase 2
Start date	March 2013
Completion date	February 2015

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03971201` - A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion	Phase 2
Recruiting	`NCT05489250` - The PLATON Network
Recruiting	`NCT04484636` - PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)	N/A
Completed	`NCT01967823` - T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer	Phase 2
Terminated	`NCT00878215` - Clinical Application of Image-Guided Liver Surgery	Phase 2
Completed	`NCT04212286` - Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC	N/A
Recruiting	`NCT05992220` - Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion	Phase 2
Completed	`NCT02073435` - A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation
Active, not recruiting	`NCT01522937` - A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer	Phase 2
Terminated	`NCT05061537` - Study of PF-07263689 in Participants With Selected Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT04166240` - Measuring and Improving the Safety of Test Result Follow-Up	N/A
Withdrawn	`NCT02288507` - Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer	Phase 1
Terminated	`NCT03026803` - A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer	Phase 2
Active, not recruiting	`NCT04682847` - Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Recruiting	`NCT05100082` - Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma
Active, not recruiting	`NCT03195699` - Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers	Phase 1
Completed	`NCT02616692` - HCC Patient Preferences in Japan	N/A
Active, not recruiting	`NCT03132792` - AFPᶜ³³²T in Advanced HCC	Phase 1
Not yet recruiting	`NCT06239194` - Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT01849588` - Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C	Phase 4